Cyclodextrins in drug delivery

Expert Opinion on Drug Delivery

Volumn 2, Issue 2, 2005, Pages 335-351

  Loftsson, Thorsteinn ^a   Jarho, Pekka ^b   Másson, Már ^a   Järvinen, Tomi ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Absorption; Bioavailability; Cyclodextrin; Drug delivery; Formulation; Solubilisation; Stabilisation

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; BENEXATE; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CARBAMAZEPINE; CEFOTIAM; CHLORAMBUCIL; CHLORAMPHENICOL; CISAPRIDE; CLOROCIL; CYCLODEXTRIN DERIVATIVE; DEXAMETHASONE; DICLOFENAC; DIGOXIN; ESTRADIOL; GAMMA CYCLODEXTRIN; GAMMA CYCLODEXTRIN DERIVATIVE; GLIBENCLAMIDE; GLYCERYL TRINITRATE; GLYMESASON; INDOMETACIN; ITRACONAZOLE; MITOEXTRA; MITOMYCIN C; NICOTINE GUM; NITROPEN; OLIGOSACCHARIDE; PIROXICAM BETA CYCLODEXTRIN; PROSTAVASIN; TIAPROFENIC ACID; UNINDEXED DRUG; VOLTAREN OPHTHA; VORICONAZOLE; ZIPRASIDONE;

AQUEOUS SOLUTION; CHEMICAL STRUCTURE; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MEMBRANE PERMEABILITY; MOLECULAR SIZE; NONHUMAN; OINTMENT; PROCESS OPTIMIZATION; REVIEW; SUPPOSITORY; SURFACE PROPERTY; TABLET FORMULATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; HUMANS; INJECTIONS; OPHTHALMIC SOLUTIONS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 23644462081     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.1.335     Document Type: Review

References (156)

1. LOFTSSON T: Cyclodextrins and the biopharmaceutics classification system. J. Incl. Phenom. Macrocycl. Chem. (2002) 44:63-67.
2. DRESSMAN J, BUTLER J, HEMPENSTALL J, REPPAS C: The BCS: where do we go from here? Pharm. Tech. North Am. (2001) 25(7):68-76.
3. LIPINSKI CA: Drug-like properties and the cause of poor solubility and poor permeability. J. Pharmacol. Toxicol. Meth. (2000) 44:235-249.
4. AMIDON GL, LENNERNÄS H, SHAH VP, CRISON JR: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. (1995) 12:413-420.
5. VILLIERS A: Sur la fermentation de la fécule par l'action du ferment butyriqué. C.R. Hebd. Seances Acad. Sci. (1891) 112:536-538.
6. SZEJTLI J: Cyclodextrin Technology, Kluwer Academic Publisher, Dordrecht, The Netherlands (1988).
7. DUCHÊNE D (Ed.): New trends in cyclodextrins and derivatives. (1991) Editions de Santé: Paris.
8. FRÖMMING KH, SZEJTLI J: Cyclodextrins in pharmacy, Kluwer Academic Publishers, Dordrecht, The Netherlands (1994).
9. LOFTSSON T, BREWSTER ME: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. (1996) 85:1017-1025.
10. RAJEWSKI RA, STELLA VJ: Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. (1996) 85:1142-1168.
11. IRIE T, UEKAMA K: Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. (1997) 86:147-162.
12. STELLA VJ, RAJEWSKI RA: Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. (1997) 14:556-567.
13. UEKAMA K (Ed.): Cyclodextrins in drug delivery. Adv. Drug Deliv. Rev. (1999) 36(1).
14. D'SOUZA VT, LIPKOWITZ KB (Eds.): Cyclodextrins. Chem. Rev. (1998) 98(5).
15. THOMPSON DO: Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. (1997) 14:1-104.
16. ZHANG M-Q, REES DC: A review of recent applications of cyclodextrins for drug discovery. Expert Opin. Ther. Patents (1999) 9:1697-1717.
17. DEL VALLE EMM: Cyclodextrins and their uses: a review. Process Biochem. (2004) 39:1033-1046.
18. UEKAMA K: Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. (2004) 52:900-915.
19. FRENCH D: The Schardinger dextrins. Adv. Carboh. Chem. (1957) 12:189-260.
20. Evaluation of Certain Food Additives and Contaminants, WHO Technical Report Series No. 909. (2002) 41-42.
21. SZENTE L, SZEJTLI J, KIS GL: Spontaneous opalescence of aqueous γ-cyclodextrin solutions: complex formation or self-aggregation. J. Pharm Sci. (1998) 87:778-781.
22. LIU L, GUO Q-X: The driving forces in the inclusion complexation of cyclodextrins. J. Incl. Phenom. Macroc. Chem. (2002) 42:1-14.
23. HIRAYAMA F, UEKAMA K: Methods of investigating and preparing inclusion compounds. In: Cyclodextrins and their industrial uses. DUCHÊNE D (Ed.) Editions de Santé, Paris (1987):131-172.
24. BREWSTER ME, LOFTSSON T: Complexation - use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations. In: Injectable drug development. Techniques to reduce pain and irritation. Gupta PK, Brazeau CA (Eds), Interpharm Press, Denver, USA (1999):307-336.
25. HIROSE K: A practical guide for the determination of binding constants. J. Incl. Phenom. Macroc. Chem. (2001) 39:193-209.
26. HIGUCHI T, CONNORS KA: Phase-solubility techniques. Adv. Anal. Chem. Instrum. (1965) 4:117-212.
27. LOFTSSON T, MAGNÚSDÓTTIR A, MÁSSON M, SIGURJÓNSDÓTTIR JF: Self-association and cyclodextrin solubilization of drugs. J. Pharm. Sci. (2002) 91:2307-2316.
28. LOFTSSON T, MÁSSON M, BREWSTER ME: Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. (2004) 93:1091-1099.
29. CONNORS KA: Population characteristics of cyclodextrin complex stabilities in aqueous solution. J. Pharm. Sci. (1995) 84:843-848.
30. CONNORS KA: The stability of cyclodextrin complexes in solution. Chem. Rev. (1997) 97:1325-1357.
31. RAO VM, STELLA VJ: When can cyclodextrins be considered for solubilizing purposes? J. Pharm. Sci. (2003) 92:927-932.
32. HEDGES AR: Industrial applications of cyclodextrins. Chem. Rev. (1998) 98:2035-2044.
33. LOFTSSON T, MÁSSON M, SIGURJÓNSDÓTTIR JF: Methods to enhance the complexation efficiency of cyclodextrins. S.T.P. Pharma Sci. (1999) 9:237-242.
34. LOFTSSON T, MÁSSON M: The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. J. Drug Del. Sci. Tech. (2004) 14:35-43.
35. KRISHNAMOORTHY R, MITRA AK: Complexation of weak acids and basis with cyclodextrins: effects of substrate ionization on the estimation and interpretation of association constants. Int. J. Pharm. Advances (1996) 1:330-343.
36. REDENTI E, SZENTE L, SZEJTLI J: Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci. (2001) 90:979-986.
37. REDENTI E, SZENTE L, SZEJTLI J: Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci. (2000) 89:1-8.
38. LOFTSSON T, SIGURDSSON HH, MÁSSON M, SCHIPPER N: Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie (2004) 59:25-29.
39. LOFTSSON T, MATTHÍASSON K, MÁSSON M: The effects of organic salts on the cyclodextrin solubilization of drugs. Int. J. Pharm. (2003) 262:101-107.
40. LI P, TABIBI E, YALKOWSKY SH: Combined effect of complexation and pH on solubilization. J. Pharm. Sci. (1998) 87:1535-1537.
41. MÁSSON M, PITHA J, LOFTSSON T: Synthesis of cycloc glycerol ether cyclodextrin derivatives and investigation of their binding properties with drugs. J. Incl. Phenom. Macroc. Chem. (1999) 33:459-467.
42. LOFTSSON T: Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stability (1995) 1:22-33.
43. MASSON M, LOFTSSON T. Evaluation of degradation studies performed in aqueous cyclodextrin solutions. In: Proceedings of the ninth international symposium of cyclodextrins. Torres Labandeira JJ, Vila-Jato JL (Eds), Kluwer Academic Publishing, Dordrecht, The Netherlands (1998):265-268.
44. MASSON M, LOFTSSON T, JÓNSDÓTTIR S, FRIDRIKSDÓTTIR H, PETERSEN DS: Stabilisation of drugs through complexation with non-ionic and ionic cyclodextrins. Int. J. Pharm. (1998) 164:45-55.
45. LOFTSSON T, JÓNSDÓTTIR B, BALDVINSDÓTTIR J, FRIDRIKSDÓTTIR H: Effect of cyclodextrins on the degradation of cortisone acetate æstradiol benzoate and prednicarbate in aqueous solution. S.T.P. Pharma Sci. (1994) 4:354-358.
46. LOFTSSON T, BJÖRNSDÓTTIR S, PÁLSDÓTTIR G, BODOR N: The effects of 2-hydroxypropyl-β-cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solution. Int. J. Pharm. (1989) 57:63-72.
47. LOFTSSON T, FRIDRIKSDOTTIR H: Degradation of lomustine (CCNU) in aqueous solutions. Int. J. Pharm. (1990) 62:243-247.
48. LOFTSSON T, OLAFSDOTTIR BJ, BALDVINSDOTTIR J: Estramustine: hydrolysis, solubilization, and stabilization in aqueous solutions. Int. J. Pharm. (1992) 79:107-112.
49. 7m-β-CD, and HP-β-CD on stability. J. Pharm. Sci. (2004) 93:532-539.
50. UEKAMA K, HIRAYAMA F, YAMADA Y, INABA K, IKEDA K: Improvements of dissolution characteristics and chemical-stability of 16,16-dimethyl-trans-delta-2-prostaglandin-E1 methylester by cyclodextrin complexation. J. Pharm. Sci. (1979) 68:1059-1060.
51. HIRAYAMA F, KURIHARA M, UEKAMA K: Improving the aqueous stability of prostaglandin-E2 and prostaglandin-A2 by inclusion complexation with methylated α-cyclodextrins. Chem. Pharm. Bull. (1984) 32:4237-4240.
52. UEKAMA K, HIEDA Y, HIRAYAMA F et al.: Stabilizing and solubilizing effects of sulfobutylether β-cyclodextrin on prostaglandin E1 analogue. Pharm. Res. (2002) 18:1578-1585.
53. JARHO P, URTTI A, JÄRVINEN T: Hydroxypropyl-β-cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Pharm. Res. (1995) 12:1371-1375.
54. 7m-β-CD. J. Pharm. Sci. (1998) 87:926-930.
55. LI JJ, GUO YS, ZOGRAFI G: The solid-state stability of amorphous quinapril in the presence of β-cyclodextrin. J. Pharm. Sci. (2002) 91:229-243.
56. WU WM, WU J, BODOR N: Effect of 2-hydroxypropyl-β-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs. Pharmazie (2002) 57:130-134.
57. TAKAHASHI K: Organic reactions mediated by cyclodextrins. Chem. Rev. (1998) 98:2013-2033.
58. TØNNESEN HH: Formulation and stability testing of photolabile drugs. Int. J. Pharm. (2001) 225:1-14.
59. BRANCHU S, FORBES RT, YORK P et al.: Hydroxypropyl-β-cyclodextrin inhibits spray-drying-induced inactivation of β-galactosidase. J. Pharm. Sci. (1999) 88:905-911.
60. SIGURJONSDOTTIR JF, LOFTSSON T, MASSON M: Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int. J. Pharm. (1999) 186:205-213.
61. KANG FR, JIANG G, HINDERLITER A, DELUCA PP, SING J: Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm. Res. (2002) 19:629-633.
62. JARHO P, VANDER VELDE D, STELLA VJ: Cyclodextrin-catalyzed deacetylation of spironolactone is pH and cyclodextrin dependent. J. Pharm. Sci. (2000) 89:241-249.
63. LOFTSSON T, ÓLAFSDÓTTIR BJ: Cyclodextrin-accelerated degradation of β-lactam antibiotics in aqueous solutions. Int. J. Pharm. (1991) 67:R5-R7.
64. LOFTSSON T, JÓHANNESSON HR: The influence of cyclodextrins on the stability of cephalotin and aztreonam in aqueous solutions. Pharmazie (1994) 49:292-293.
65. MOLDENHAUER J: Wacker-Chemie GmbH: Burghausen (2004).
66. LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46:3-26.
67. MATSUDA H, ARIMA H: Cyclodextrins in transdermal and rectal delivery. Adv. Drug Deliv. Rev. (1999) 36:81-99.
68. UEKAMA K, HIRAYAMA F, IRIE T: Cyclodextrin drug carrier systems. Chem. Rev. (1998) 98:2045-2076.
69. LEGENDRE JY, RAULT I, PETIT A et al.: Effects of β-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur. J. Pharm. Sci. (1995) 3:311-322.
70. VITÓRIA M, BENTLEY B, RENATA F, WILSON S, COLLETT JH: Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol. (1997) 49:397-402.
71. ARIMA H, MIYAJI T, IRIE T, HIRAYAMA F, UEKAMA K: Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by β-cyclodextrin derivatives in hydrophilic ointment. Chem. Pharm. Bull. (1996) 44:582-586.
72. ARIMA H, MIYAJI T, IRIE T, HIRAYAMA F,UEKAMA K: Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration activation of ethyl 4-biphenylyl acetate in hairless mouse skin. Eur. J. Pharm. Sci. (1998) 6:53-59.
73. LOFTSSON T, MASSON M: Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. (2001) 225:15-30.
74. LOFTSSON T, SIGFÚSSON SD, SIGURDSSON HH, MÁSSON M: The effects of cyclodextrins on topical delivery of hydrocortisone: the aqueous diffusion layer. S.T.P. Pharma Sci. (2003) 13:125-131.
75. MARTTIN E, VERHOEF JC, MERKUS FW: Efficiency, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. (1998) 6:17-36.
76. IRIE T, WAKAMATSU K, ARIMA H, ARITOMI H, UEKAMA K: Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm. (1992) 84:129-139.
77. LOFTSSON T, BREWSTER ME, MÁSSON M: Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. (2004) 2:261-275.
78. HARRIS D, ROBINSON JR: Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. (1992) 82:1-10.
79. HOON TJ, DAWOOD MY, KHAN-DAWOOD FS, RAMOS J, BATENHORST RL: Bioequivalence of 17β-Estradiol Hydroxypropyl-β-Cyclodextrin Complex in Postmenopausal Women. J. Clin. Pharmacol. (1993) 33:1116-1121.
80. FRIDRIKSDÓTTIR H, LOFTSSON T, GUDMUNDSSON JA et al.: Design and in vivo testing of 17β-estradiol-HPβCD sublinqual tablets. Pharmazie (1996) 51:39-42.
81. BROWN GA, MARTIN ER, ROBERTS BS, VUKOVICH MD, KING DS: Acute hormonal response to sublingual androstenediol in young men. J. Appl. Physiol. (2002) 92:142-146.
82. YOO SD, YOON BM, LEE HS, LEE KC: Increased bioavailability of clomipramine after sublingual administration in rats. J. Pharm. Sci. (1999) 88:1119-1121.
83. BADAWY SIF, GHORAB MM, ADEYEYE CM: Bioavailability of danazol-hydroxypropyl-β-cyclodextrin complex by different routes of administration. Int. J. Pharm. (1996) 145:137-143.
84. MANNILA J, JÄRVINEN T, LEHTONEN M et al.: Effects of RM-α-CD on bioavailability of THC. Proceedings of the AAPS annual meeting and exposition. Salt Palace Convention Center, Salt Lake City, USA (2003).
85. BEHL CR, PIMPLASKAR HK, SILENO AP, DEMEIRELES J, ROMEO VD: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Del. Rev. (1998) 29:89-116.
86. MERKUS FWHM, VERHOEF JC, MARTTIN E et al.: Cyclodextrin in nasal drug delivery. Adv. Drug Deliv. Rev. (1999) 36:41-57.
87. HERMENS WA, DEURLOO MJ, ROMEIJN SG, VERHOEF JC, MERCUS FW: Nasal absorption enhancement of 17β-estradiol by dimethyl-β-cyclodextrin in rabbits and rats. Pharm. Res. (1990) 7:500-503.
88. MATSUBARA K, ABE K, IRIE T, UEKAMA K: Improvement of nasal bioavailability of lutenizing hormone releasing hormone agonist buserelin by cyclodextrin complexationin rats. J. Pharm. Sci. (1995) 84:1295-1300.
89. KUBLIK H, BOCK TK, SCHREIER H, MÜLLER BW: Nasal absorption of 17β-estradiol from different cyclodextrin inclusion formulations in sheep. Eur. J. Pharm. Biopharm. (1996) 42:320-324.
90. SCHIPPER NG, HERMENS WA, ROMEYN SG, VERHOEF J, MERKUS FW: Nasal absorption of 17-β-estradiol and progesterone from dimethyl-cyclodextrin inclusion formulation in rats. Int. J. Pharm. (1990) 64:61-66.
91. MERKUS FW, VERHOEF J, ROMEIJN SG, SCHIPPER NG: Absorption enhancing effect of cyclodextrins in itranasally administered insulin in rats. Pharm. Res. (1991) 8:588-592.
92. MARTTIN E, ROMEIJN SG, VERHOEF JC, MERKUS FW: Nasal absorption of dihydroergotamine from liquid and powder formulations in rabbits. J. Pharm. Sci. (1997) 86:802-807.
93. LOFTSSON T, GUDMUNDSDOTTIR H, SIGURJONSDOTTIR JF et al.: Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int. J. Pharm. (2001) 212:29-40.
94. CHAVANPATIL MD, VAVIA PR: The influence of absorption enhancers on nasal absorption of acyclovir. Eur. J. Pharm. Biopharm. (2004) 57:483-487.
95. YANG T, HUSSAIN A, PAULSON J, ABBRUSCATO TJ, AHSAN F: Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm. Res. (2004) 21:1127-1136.
96. MARTTIN E, VERHOEF JC, ROMEIJN SG, ZWART P, MERKUS FWHM: Acute histopathological effects of benzalconium chloride and absorption enhancers in rat nasal epithelium in vivo. Int. J. Pharm. (1996) 141:151-160.
97. ROMEIJN SG, VERHOEF JC, MARTTIN E, MERKUS FW: The effect of nasal drug formulations on ciliary beating in vitro. Int. J. Pharm. (1996) 135:137-145.
98. WASHINGTON N, WASHINGTON C, WILSON CG: Pulmonary drug delivery. In: Physiological Pharmaceutics. Barriers to drug absorption (2nd Edition). Taylor & Francis, London, UK (2001):221-247.
99. CABRAL MARQUES HM, HADGRAFT J, KELLAWAY IW, TAYLOR G: Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrins in rabbits. Int. J. Pharm. (1991) 77:297-302.
100. NIMBALKAR D, BIRUDARAJ R, JONES PR, SMITH TJ: Activation of diacetyldapsone and a preliminary evaluation of a cyclodextrin-diacetyldapsone complex in cultured lung cells. Biotechnol. Appl. Biochem. (2001) 33:123-125.
101. KINNARINEN T, JÄRVINEN K, JARHO P et al.: Cyclodextrins in pulmonary drug delivery: in vitro toxicity of cyclodextrins in calu-3 cells. In: Respiratory drug delivery IX. Desert Springs Marriot Resort & Spa, Palm Desert, CA, USA (2004).
102. PRIME D, ATKINS PJ, SLATER A, SUMBY B: Review of dry powder inhalers. Adv. Drug Deliv. Rev. (1997) 26:51-58.
103. SRICHANA T, SUEDEE R, REANMONGKOL W: Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir. Med. (2001) 95:513-519.
104. LEITE PINTO JM, CABRAL MARQUES HM: Beclomethasone/cyclodextrin inclusion complex for dry powder inhalation. S.T.P. Pharma Sci. (1999) 9:253-256.
105. SHAO Z, LI Y, MITRA AK: Cyclodextrins as mucosal absorption promoters of insulin. III. Pulmonary route of delivery. Eur. J. Pharm. Biopharm. (1994) 40:283-288.
106. SHAO ZJ, MITRA AK: Pulmonary absorption of recombinant human growth hormone in rats. Eur. J. Pharm. Biopharm. (1996) 42:199-203.
107. WALL DA, MARCELLO J, PIERDOMENICO D, FARID A: Administration as hydroxypropyl β-cyclodextrin complexes does not slow rates of pulmonary drug absorption in rats. S.T.P. Pharma Sci. (1994) 4:63-68.
108. KINNARINEN T, JARHO P, JÄRVINEN K, JÄRVINEN T: Pulmonary deposition of a budesonide/γ-cyclodextrin complex in vitro. J. Control. Rel. (2003) 90.
109. STRICKLEY RG: Solubilizing excipients in oral and injectable formulations. Pharm. Res. (2004) 21:201-230.
110. LOFTSSON T, BREWSTER ME, DERENDORF H, BODOR N: 2-Hydroxypropyl-β-cyclodextrin: properties and usage in pharmaceutical formulations. Pharm. Ztg. Wiss. (1991) 136:5-10.
111. DIETZEL K, ESTES KS, BREWSTER ME, BODOR NS, DERENDORF H: The use of 2-Hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. Int. J. Pharm. (1990) 59:225-230.
112. STELLA VJ, RAO VM, ZANNOU EA, ZIA V: Mechanism of drug release from cyclodextrin complexes. Adv. Drug Deliv. Rev. (1999) 36:3-16.
113. WASHINGTON N, WASHINGTON C, WILSON CG: Ocular drug delivery. In: Physiological pharmaceutics: barriers to drug absorption. Taylor & Francis, London, UK (2001):249-270.
114. URTTI A, SALMINEN L: Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. (1993) 37:435-456.
115. LOFTSSON T, JÄRVINEN T: Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. (1999) 36:59-79.
116. LOFTSSON T, STEFÁNSSON E: Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol. Scand. (2002) 80:144-150.
117. LOFTSSON T, FRIDRIKSDOTTIR H, STEFANSSON E et al.: Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J. Pharm. Pharmacol. (1994) 46:503-504.
118. SUHONEN P, JARVINEN T, LEHMUSSAARI K, REUNAMAKI T, URTTI A: Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharm. Res. (1995) 12:529-533.
119. SHAKER DS, GHANEM A-H, LI SK et al.: Mechanistic studies of the effect of hydroxypropyl-β-cyclodextrin on in vitro transdermal permeation of corticosterone through hairless mouse skin. Int. J. Pharm. (2003) 253:1-11.
120. PREISS A, MEHNERT W, FRÖMMING KH: In-vitro hydrocortisone release from ointments in presence of cyclodextrins. Pharmazie (1994) 49:902-906.
121. PREISS A, MEHNERT W, FRÖMMING K-H: Penetration of hydrocortisone into excised human skin under the influence of cyclodextrins. Pharmazie (1995) 50:121-126.
122. ADACHI H, IRIE T, UEKAMA K et al.: Inhibitory effect of prostaglandin E1 on laurate-induced peripheral vascular occlusive sequelae in rabbits; optimized topical formulation with β-cyclodextrin derivative and penetration enhancer HPE-101. J. Pharm. Pharmacol. (1992) 44:1033-1035.
123. ADACHI H, IRIE T, UEKAMA K et al.: Combination effects of O-carboxymethyl-O-ethyl-β-cyclodextrin and penetration enhancer HPE-101 on transdermal delivery of prostaglandin-E(1) in hairless mice. Eur. J. Pharm. Sci. (1993) 1:117-123.
124. LOFTSSON T, MASSON M, SIGURDSSON HH, MAGNUSSON P, GOFFIC FL: Cyclodextrins as co-enhancers in dermal and transdermal drug delivery. Pharmazie (1998) 53:137-139.
125. FELTON LA, WILEY CJ, GODWIN DA: Influence of hydroxypropyl-β-cyclodextrin on transdermal permeation and skin accumulation of oxybenzone. Drug Dev. Ind. Pharm. (2002) 28:1117-1124.
126. FELTON LA, WILEY CJ, GODWIN DA: Influence of cyclodextrin complexation on the in vivo photoprotective effects of oxybenzone. Drug Dev. Ind. Pharm. (2004) 30:95-102.
127. ELKHESHEN SA, AHMED SM, AL-QUADEIB BT: Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin - 2nd communication: in vitro and in vivo drug availability. Pharmazeutische Industrie (2002) 64:708-715.
128. WOODCOCK BG, ACERBI D, MERZ PG, RIETBROCK S, RIETBROCK N: Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur. J. Rheumat. Inflamm. (1993) 12:12-28.
129. KIMURA E, BERSANI-AMADO CA, SUDO LS, SANTOS SRJ, OGA S: Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymph. Gen. Pharmac. (1997) 28:695-698.
130. DEROUBAIX X, STOCKIS A, ALLEMON AM et al.: Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy-subjects under single-dose and steady-state conditions. Eur. J. Clin. Pharmacol. (1995) 47:531-536.
131. MCEWEN J: Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care. Clin. Drug Invest. (2000) 19(Suppl. 2):27-31.
132. EL-GINDY GA, MOHAMMED FA, SALEM SY: Preparation, pharmacokinetic and pharmacodynamic evaluation of carbamazepine inclusion complexes with cyclodextrins. S.T.P. Pharma Sci. (2002) 12:369-378.
133. BREWSTER ME, ANDERSON WR, MEINSMA D et al.: Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J. Pharm. Sci. (1997) 86:335-339.
134. BETLACH CJ, GONZALEZ MA, MCKIERNAN BC, NEFEDAVIS C, BODOR N: Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. J. Pharm. Sci. (1993) 82:1058-1060.
135. CHOUDHURY S, NELSON KF: Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-β-cyclodextrin. Int. J. Pharm. (1992) 85:175-180.
136. KOESTER LS, BERTUOL JB, GROCH KR et al.: Bioavailability of carbamazepine:β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur. J. Pharm. Sci. (2004) 22:201-207.
137. UEKAMA K, FUJINAGA T, HIRAYAMA F et al.: Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J. Pharm. Sci. (1983) 72:1338-1341.
138. SAVOLAINEN J, JÄRVINEN K, TAIPALE H et al.: Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid dosage forms. Pharm. Res. (1998) 15:1696-1701.
139. JAYACHANDRA BABU R, PANDIT JK: Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with β-cyclodextrin. S.T.P. Pharma Sci. (1995) 5:196-201.
140. TENJARLA S, PURANAJOTI P, KASINA R, MANDAL T: Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J. Pharm. Sci. (1998) 87:425-429.
141. UEKAMA K, OTAGIRI M, IRIE T, SEO H, TSURUOKA M: Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble β-cyclodextrin-epichlorohydrin polymer. Int. J. Pharm. (1985) 23:35-42.
142. TANINO T, OGISO T, IWAKI M: Effect of sugar-modified β-cyclodextrins on dissolution and absorption characteristics of phenytoin. Biol. Pharm. Bull. (1999) 22:298-304.
143. 7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation. Int. J. Pharm. (1998) 165:69-78.
144. KAUKONEN AM, LENNERNÄS A, MANNERMAA JP: Water-soluble β-cyclodextrins in pediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats. J. Pharm. Pharmacol. (1998) 50:611-619.
145. SOLIMAN OAE, KIMURA K, HIRAYAMA F et al.: Amorphous spirolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int. J. Pharm. (1997) 149:73-83.
146. SEO H, TSURUOKA M, HASHIMOTO T et al.: Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem. Pharm. Bull. (1983) 31:286-291.
147. VEIGA F, FERNANDES C, TEIXEIRA T: Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int. J. Pharm. (2000) 202:165-171.
148. KIMURA K, HIRAYAMA F, ARIMA H, UEKAMA K: Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-β-cyclodextrin complex. Chem. Pharm. Bull. (2000) 48:646-650.
149. UEKAMA K, HORIUCHI Y, KIKUCHI M, HIRAYAMA F: Enhanced dissolution and oral bioavailability of α-tocopheryl esters by dimethyl-β-cyclodextrin complexation. J. Incl. Phenom. (1988) 6:167-174.
150. LUENGO J, ARÁNGUIZ T, SEPÚLVEDA J, HERNÁNDEZ L, VON PLESSING C: Preliminary pharmacokinetic study of different preparations of acyclovir with β-cyclodextrin. J. Pharm. Sci. (2002) 91:2593-2598.
151. LE CORRE P, DOLLO G, CHEVANNE F, LE VERGE R: Influence of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model. Int. J. Pharm. (1998) 169:221-228.
152. MIYAKE K, ARIMA H, IRIE T, HIRAYAMA F, UEKAMA K: Enhanced absorption of cyclosporin A by complexation with dimethyl-β-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol. Pharm. Bull. (1999) 22:66-72.
153. MIYAKE K, IRIE T, HIRAYAMA F, UEKAMA K: Improved solubility and oral bioavailability of cyclosporin A by hydrophilic cyclodextrin complexation. In: Proceedings of the ninth international symposium on cyclodextrins. JJ Torres Labandeira and JL Vila-Jato (Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands (1999):293-296.
154. TRISSEL LA (Ed.): Handbook on Injectable Drugs (12th Edition). American Society of Health-System Pharmacists, Bethesda, MD, USA (2003).
155. BLANCHARD J, UGWU SO, BHARDWAJ R, DORR RT: Development and testing of an improved parenteral formulation of phenytoin using 2-hydroxypropyl-β-cyclodextrin. Pharm. Dev. Technol. (2000) 5:333-338.
156. JARHO P, URTTI A, PATE DW, SUHONEN P, JÄRVINEN T: Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. Int. J. Pharm. (1996) 137:209-217.